Research record
Nivolumab + relatlimab
A combination immune checkpoint treatment that pairs PD-1 blockade with LAG-3 blockade. It belongs in immunotherapy discussions, not targeted-therapy mutation discussions.
What this is
A combination immune checkpoint treatment that pairs PD-1 blockade with LAG-3 blockade. It belongs in immunotherapy discussions, not targeted-therapy mutation discussions.
Why it may come up
- melanoma that cannot be removed by surgery
- melanoma that has spread
What not to assume
- Do not present as preferred over other immunotherapy combinations.
- Do not infer availability in Korea, China, or Japan from U.S. FDA approval.
At a glance
Nivolumab + relatlimab
- Type
- Immunotherapy
- Mutation result
- any
- Where
- US
- Evidence status
- Approved in listed place
- Last checked
- 2026-05-20
What we know
- FDA approval page is the primary source.
- Country-by-country access outside the U.S. still needs mapping.
What is unclear
- Do not present as preferred over other immunotherapy combinations.
- Do not infer availability in Korea, China, or Japan from U.S. FDA approval.
Questions to ask
- How does this compare with nivolumab plus ipilimumab in this case?
- Is this being discussed before or after prior immunotherapy?
- What immune-related side effects are most important to watch for?
Timeline
- approval2022: FDA approval source
Nivolumab plus relatlimab-rmbw FDA approval context for unresectable/metastatic melanoma.